Division of General Surgery, Department of Surgery, Toronto, Canada.
Division of Vascular and Interventional Radiology, Department of Medical Imaging, Toronto, Canada.
HPB (Oxford). 2019 Aug;21(8):1072-1078. doi: 10.1016/j.hpb.2018.12.009. Epub 2019 Feb 20.
Portal vein embolization (PVE) is used before major hepatectomy for hepatocellular carcinoma (HCC) to increase future liver remnant (FLR) volume. However, this may increase tumour growth rate, leading to more extensive resections. This study aimed to determine the effect of tumour growth, following PVE, on treatment plan.
Retrospective cohort study conducted on patients treated from 2008 to 2015 with PVE before major hepatectomy for HCC. Liver and tumour volumetry was performed on pre- and post-PVE CT scans. Image-based and actioned plans were compared before and after PVE.
Thirty-one patients received PVE. Non-tumour total liver volume decreased (median 1440 to 1394 cm; p = 0.031), while tumour (median 161-240 cm; p < 0.001) and FLR volumes (median 430-574 cm; p < 0.001) increased. The treatment plan changed in 15/31 patients: more extensive resection (n = 6), less extensive resection (n = 1), no resection as scheduled (n = 8). Tumour progression accounted for a clinically relevant change in treatment plan in 8/31 patients.
Following PVE in the setting of HCC, tumour progression accounts for a change in treatment plan in approximately a quarter of patients. Further research is warranted to determine whether additional liver directed therapy should routinely be used to slow the growth of HCC post-PVE.
门静脉栓塞术(PVE)用于肝癌(HCC)的大肝切除术前,以增加未来肝残留(FLR)体积。然而,这可能会增加肿瘤生长速度,导致更广泛的切除。本研究旨在确定 PVE 后肿瘤生长对治疗计划的影响。
对 2008 年至 2015 年期间接受 PVE 治疗的 HCC 大肝切除术前患者进行回顾性队列研究。在 PVE 前后的 CT 扫描上进行肝和肿瘤体积测量。比较 PVE 前后的基于图像和行动的计划。
31 例患者接受了 PVE。非肿瘤总肝体积减少(中位数 1440 至 1394cm;p=0.031),而肿瘤(中位数 161-240cm;p<0.001)和 FLR 体积(中位数 430-574cm;p<0.001)增加。31 例患者中有 15 例治疗计划发生变化:更广泛的切除(n=6),较不广泛的切除(n=1),按计划无切除(n=8)。肿瘤进展导致 8/31 例患者的治疗计划发生了临床相关的变化。
在 HCC 患者中进行 PVE 后,肿瘤进展导致约四分之一患者的治疗计划发生改变。需要进一步研究以确定是否应常规使用额外的肝脏定向治疗来减缓 PVE 后 HCC 的生长。